Variagenics Posts Miniscule Revenue, Widened Loss in Q4 | GenomeWeb

NEW YORK, Feb. 26 - Variagenics on Tuesday said that a significant drop in fourth-quarter total revenue conspired with increased R&D costs to send net loss spiraling skyward.

Revenue for the period ended Dec. 31 was $392,000, down from $1.2 million on year, and was attributable exclusively to research collaborations. Variagenics' sales in the current fourth quarter echoed last year's, as there were no sales of the company's NuCleave genotyping system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.